Mereo BioPharma Group plc (NASDAQ:MREO) Receives Consensus Rating of “Buy” from Brokerages
Mereo BioPharma Group plc (NASDAQ:MREO – Get Free Report) has been given an average rating of “Buy” by the seven brokerages that are currently covering the firm, MarketBeat reports. Four research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. The average 12-month price […]
